PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING
Objectives: The objective of this study is to examine neuroblastoma patients that were examined by next generation sequencing (NGS) for targeted therapy related specific gene mutations including Anaplastic Lymphoma Kinase (ALK) Materials and Methods: Molecular examinations of neuroblastoma according...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2022-08-01
|
| Series: | Sabiad |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/9403107D00EA45AA90E4089CDFF72E16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850033921753874432 |
|---|---|
| author | Tekincan Çağrı Aktaş Deniz Kızmazoğlu Safiye Aktaş Özde Gökbayrak Emre Çeçen Dilek İnce Zekiye Altun Nur Olgun |
| author_facet | Tekincan Çağrı Aktaş Deniz Kızmazoğlu Safiye Aktaş Özde Gökbayrak Emre Çeçen Dilek İnce Zekiye Altun Nur Olgun |
| author_sort | Tekincan Çağrı Aktaş |
| collection | DOAJ |
| description | Objectives: The objective of this study is to examine neuroblastoma patients that were examined by next generation sequencing (NGS) for targeted therapy related specific gene mutations including Anaplastic Lymphoma Kinase (ALK) Materials and Methods: Molecular examinations of neuroblastoma according to Turkish Pediatric Oncology Group protocols (Nmyc amplification, 11q23 deletion, 1p36 deletion, DNA ploidy by Cell cycle kit in flow cytometer) is studied in our department in all cases collected from Turkey. Among these cases, the patients that recurred even after multi model therapies, are requested NGS to evaluate for targeted therapy decision. We study single nucleated variations after DNA isolation using Pillar Onco/Reveal Multicancer v4 with CNV Panel with 60 genes (ALK, BRAF, ERB2, PIK3CA, EGFR, KRAS, MET, ….) on İllumina Miniseq platform. Results: We especially reported ALK mutations which has indication for crizotinib or alectinib. Out of our investigated patients only 22% (9/41) had ALK mutations. Two patients (22%) had R1275Q mutation, six patients (66,7%) had F1174L mutation and one patient (11%) had L1226F, S1189F, V1135A and G1225S mutations. Conclusion: Our patient cohort seems to be showing ALK mutations and F1174L (sensitive to alectinib) mutation more often than R1275Q mutation (sensitive to crizotinib) in neuroblastoma cases. The reason that ALK mutation ratio is higher than literature. The reason of this might be because of selection of patients by the clinicians. These patients received targeted therapies and had longer survival. |
| format | Article |
| id | doaj-art-e612ccdbd7ba43b6834fd265abf1818e |
| institution | DOAJ |
| issn | 2651-4060 |
| language | English |
| publishDate | 2022-08-01 |
| publisher | Istanbul University Press |
| record_format | Article |
| series | Sabiad |
| spelling | doaj-art-e612ccdbd7ba43b6834fd265abf1818e2025-08-20T02:58:00ZengIstanbul University PressSabiad2651-40602022-08-0151404010.26650/JARHS2021-1134059123456PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCINGTekincan Çağrı Aktaş0Deniz Kızmazoğlu1Safiye Aktaş2Özde Gökbayrak3Emre Çeçen4Dilek İnce5Zekiye Altun6Nur Olgun7Dokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeDokuz Eylül Üniversitesi, Izmir, TurkiyeObjectives: The objective of this study is to examine neuroblastoma patients that were examined by next generation sequencing (NGS) for targeted therapy related specific gene mutations including Anaplastic Lymphoma Kinase (ALK) Materials and Methods: Molecular examinations of neuroblastoma according to Turkish Pediatric Oncology Group protocols (Nmyc amplification, 11q23 deletion, 1p36 deletion, DNA ploidy by Cell cycle kit in flow cytometer) is studied in our department in all cases collected from Turkey. Among these cases, the patients that recurred even after multi model therapies, are requested NGS to evaluate for targeted therapy decision. We study single nucleated variations after DNA isolation using Pillar Onco/Reveal Multicancer v4 with CNV Panel with 60 genes (ALK, BRAF, ERB2, PIK3CA, EGFR, KRAS, MET, ….) on İllumina Miniseq platform. Results: We especially reported ALK mutations which has indication for crizotinib or alectinib. Out of our investigated patients only 22% (9/41) had ALK mutations. Two patients (22%) had R1275Q mutation, six patients (66,7%) had F1174L mutation and one patient (11%) had L1226F, S1189F, V1135A and G1225S mutations. Conclusion: Our patient cohort seems to be showing ALK mutations and F1174L (sensitive to alectinib) mutation more often than R1275Q mutation (sensitive to crizotinib) in neuroblastoma cases. The reason that ALK mutation ratio is higher than literature. The reason of this might be because of selection of patients by the clinicians. These patients received targeted therapies and had longer survival.https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/9403107D00EA45AA90E4089CDFF72E16neuroblastomanext generation sequencinganaplastic lymphoma kinase |
| spellingShingle | Tekincan Çağrı Aktaş Deniz Kızmazoğlu Safiye Aktaş Özde Gökbayrak Emre Çeçen Dilek İnce Zekiye Altun Nur Olgun PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING Sabiad neuroblastoma next generation sequencing anaplastic lymphoma kinase |
| title | PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING |
| title_full | PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING |
| title_fullStr | PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING |
| title_full_unstemmed | PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING |
| title_short | PRECISION MEDICINE IN NEUROBLASTOMA: EXPERIENCE WITH NEXT GENERATION SEQUENCING |
| title_sort | precision medicine in neuroblastoma experience with next generation sequencing |
| topic | neuroblastoma next generation sequencing anaplastic lymphoma kinase |
| url | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/9403107D00EA45AA90E4089CDFF72E16 |
| work_keys_str_mv | AT tekincancagrıaktas precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT denizkızmazoglu precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT safiyeaktas precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT ozdegokbayrak precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT emrececen precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT dilekince precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT zekiyealtun precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing AT nurolgun precisionmedicineinneuroblastomaexperiencewithnextgenerationsequencing |